# RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment

> **NCT02190227** · PHASE2 · COMPLETED · sponsor: **Jewish General Hospital** · enrollment: 30 (actual)

## Conditions studied

- Invasive Breast Cancer

## Interventions

- **DEVICE:** Tumor RDA biopsy

## Key facts

- **NCT ID:** NCT02190227
- **Lead sponsor:** Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02190227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02190227, "RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02190227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*